Compounds > 23-hydroxybetulinic acid
Page last updated: 2024-11-13

23-hydroxybetulinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

23-hydroxybetulinic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21672692
CHEMBL ID251308
CHEBI ID69580
MeSH IDM0442970

Synonyms (24)

Synonym
23-hydroxybetulinic acid, 25
(1r,2r,5s,8r,9r,10r,13r,14r,17s,18r,19r)-17-hydroxy-18-(hydroxymethyl)-1,2,14,18-tetramethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosane-5-carboxylic acid
bdbm23209
anemosapogenin
23-hydroxybetulinic acid
chebi:69580 ,
23-hydroxy betulic acid
CHEMBL251308
23-hydroxybetulinicacid
S9009
85999-40-2
H1742
CS-5686
HY-N0566
3,23-dihydroxy-20(29)-lupen-28-oic acid
23-hydroxybetulinic acid, >=98% (hplc)
AKOS032944876
Q27137923
F16085
HXWLKAXCQLXHML-WGOZWDAUSA-N
(1r,3as,5ar,5br,7ar,8r,9s,11ar,11br,13ar,13br)-9-hydroxy-8-(hydroxymethyl)-5a,5b,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
CCG-269469
MS-28759
AC-35126

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The described assay method was successfully applied to cellular pharmacokinetic studies in a human colon adenocarcinoma cell line (Caco-2) and its application of measuring the cellular concentrations of 23-hydroxybetunilic acid could be extended to different cultured cell lines."( Quantitative analysis of 23-hydroxybetulinic acid, a novel anticancer substance, in the cellular environment of a human colon adenocarcinoma cell line for cellular pharmacokinetic studies.
Gu, Y; Li, X; Liang, Y; Lv, H; Sun, J; Wang, G; Wu, X; Yan, B; Ye, W; Zheng, Y, 2007)		0.64

Dosage Studied

ExcerptRelevanceReference
"05), and dosage time-dependent relationships were found."( 23-hydroxybetulinic acid-induced HL-60 cell autophagic apoptosis and its molecular mechanism.
Ji, ZN; Ye, B, 2012)		1.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cocaine esteraseHomo sapiens (human)IC50 (µMol)1.90000.00582.43306.8000AID1697438
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)IC50 (µMol)33.36980.01405.93249.0000AID1798302; AID404873; AID443935; AID603224
5'-nucleotidaseHomo sapiens (human)IC50 (µMol)100.00000.05002.24118.2000AID1889898
Liver carboxylesterase 1Homo sapiens (human)IC50 (µMol)0.10000.00400.25510.6000AID1697439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
prostaglandin metabolic processCocaine esteraseHomo sapiens (human)
xenobiotic metabolic processCocaine esteraseHomo sapiens (human)
catabolic processCocaine esteraseHomo sapiens (human)
DNA metabolic process5'-nucleotidaseHomo sapiens (human)
leukocyte cell-cell adhesion5'-nucleotidaseHomo sapiens (human)
response to inorganic substance5'-nucleotidaseHomo sapiens (human)
response to ATP5'-nucleotidaseHomo sapiens (human)
ADP catabolic process5'-nucleotidaseHomo sapiens (human)
ATP metabolic process5'-nucleotidaseHomo sapiens (human)
adenosine biosynthetic process5'-nucleotidaseHomo sapiens (human)
negative regulation of inflammatory response5'-nucleotidaseHomo sapiens (human)
calcium ion homeostasis5'-nucleotidaseHomo sapiens (human)
inhibition of non-skeletal tissue mineralization5'-nucleotidaseHomo sapiens (human)
AMP catabolic process5'-nucleotidaseHomo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
methylumbelliferyl-acetate deacetylase activityCocaine esteraseHomo sapiens (human)
carboxylesterase activityCocaine esteraseHomo sapiens (human)
carboxylic ester hydrolase activityCocaine esteraseHomo sapiens (human)
nucleotide binding5'-nucleotidaseHomo sapiens (human)
5'-deoxynucleotidase activity5'-nucleotidaseHomo sapiens (human)
protein binding5'-nucleotidaseHomo sapiens (human)
5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
zinc ion binding5'-nucleotidaseHomo sapiens (human)
identical protein binding5'-nucleotidaseHomo sapiens (human)
thymidylate 5'-phosphatase activity5'-nucleotidaseHomo sapiens (human)
IMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
GMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
XMP 5'-nucleosidase activity5'-nucleotidaseHomo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
endoplasmic reticulumCocaine esteraseHomo sapiens (human)
endoplasmic reticulum lumenCocaine esteraseHomo sapiens (human)
intracellular membrane-bounded organelleCocaine esteraseHomo sapiens (human)
plasma membrane5'-nucleotidaseHomo sapiens (human)
nucleoplasm5'-nucleotidaseHomo sapiens (human)
cytosol5'-nucleotidaseHomo sapiens (human)
plasma membrane5'-nucleotidaseHomo sapiens (human)
external side of plasma membrane5'-nucleotidaseHomo sapiens (human)
cell surface5'-nucleotidaseHomo sapiens (human)
membrane5'-nucleotidaseHomo sapiens (human)
extracellular exosome5'-nucleotidaseHomo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID771508Antibacterial activity against Staphylococcus aureus RN4220 by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID1165770Toxicity in human H22 cells transplanted ICR mouse assessed as mouse survival at 30 mg/kg, ip administered 7 days post tumor transplantation2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID771507Antibacterial activity against Bacillus subtilis 168 by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID404873Inhibition of rabbit muscle glycogen phosphorylase A assessed as phosphate release from glucose-1-phosphate2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
AID1165763Antiproliferative activity against human HeLa cells after 72 hrs MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1176852Antiproliferative activity against human SF763 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID1176854Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID771494Antibacterial activity against Escherichia coli by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID1176856Antitumor activity against mouse B16 cells allografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered 7 days post inoculation measured at day 25 of tumor transplantation2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID306336Cytotoxicity against mouse B16 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID603224Inhibition of rabbit muscle glycogen phosphorylase A assessed as release of phosphate from glucose-1-phosphate after 25 mins by microplate reader based method2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Identification of pentacyclic triterpenes derivatives as potent inhibitors against glycogen phosphorylase based on 3D-QSAR studies.
AID1422939Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID306334Cytotoxicity against human BEL-7402 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID771509Antibacterial activity against community associated methicillin-resistant Staphylococcus aureus USA300 by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID1165761Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1862741Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID306345Antitumor activity in B16 cells xenografted ICR mouse assessed as tumor growth inhibition at 20 mg/kg, ip after 11 days2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1422940Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1165768Antitumor activity against mouse B16 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered 7 days post tumor transplantation2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1565773Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID1422955Induction of apoptosis in mouse B16F10 cells assessed as increase in caspase-9 protein expression at 7.5 to 30 uM after 48 hrs by Western blot analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1204816In vivo antitumor activity against mouse B16 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1697439Inhibition of CES1A1 in human liver microsomes using D-luciferin methyl ester as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2020Journal of natural products, 10-23, Volume: 83, Issue:10
Bioactivity-Guided Discovery of Human Carboxylesterase Inhibitors from the Roots of
AID1697440Selectivity ratio of IC50 for inhibition of CES2A1 in human liver microsomes to IC50 for CES1A1 in human liver microsomes2020Journal of natural products, 10-23, Volume: 83, Issue:10
Bioactivity-Guided Discovery of Human Carboxylesterase Inhibitors from the Roots of
AID1565774Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID1204780Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1204783Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1204782Antiproliferative activity against human SF763 cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID600931Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
AID1862746Selectivity index, ratio of IC50 for antiproliferative activity against NQO1-deficient human NCI-H596 cells to IC50 for antiproliferative activity against human HT-29 cells overexpressing NQO12022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID623341Induction of apoptosis in human M14 cells assessed as increase in hypodiploid cells at 1 to 50 uM after 24 hrs using propidium iodide staining by flow cytometry2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID1176850Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID1176851Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID1422950Induction of mitochondrial membrane potential loss in mouse B16F10 cells at 30 uM after 48 hrs by JC-1 dye based flow cytometry (Rvb = 1.79%)2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1204784Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID306337Cytotoxicity against mouse C6 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1565777Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID771496Antibacterial activity against Acinetobacter baumannii by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID1176853Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID1165772Toxicity in human H22 cells transplanted ICR mouse assessed as mouse body weight at 30 mg/kg, ip administered 7 days post tumor transplantation (Rvb = 18.4 to 18.9g)2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1565775Antiproliferative activity against human B16 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID1165776Toxicity in mouse B6 cells transplanted ICR mouse assessed as mouse body weight at 30 mg/kg, iv administered 7 days post tumor transplantation (Rvb = 18.3 to 18.6g)2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID600933Antiproliferative activity against human A375 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
AID306341Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor growth inhibition at 20 mg/kg, ip after 4 days2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1165760Antiproliferative activity against human HL60 cells after 72 hrs MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1697438Inhibition of CES2A1 in human liver microsomes using D-luciferin methyl ester as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2020Journal of natural products, 10-23, Volume: 83, Issue:10
Bioactivity-Guided Discovery of Human Carboxylesterase Inhibitors from the Roots of
AID600932Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
AID623338Cytotoxicity against human M14 cells after 48 hrs by MTT assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID1422953Induction of apoptosis in mouse B16F10 cells assessed as increase in cytochrome-c protein expression at 7.5 to 30 uM after 48 hrs by Western blot analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1565776Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID1165766Antitumor activity against human H22 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered 7 days post tumor transplantation2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID443935Inhibition of rabbit muscle glycogen phosphorylase A assessed as release of phosphate from glucose-1-phosphate after 25 mins2009Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24
Terpenoids. III: Synthesis and biological evaluation of 23-hydroxybetulinic acid derivatives as novel inhibitors of glycogen phosphorylase.
AID600929Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
AID1422949Induction of mitochondrial membrane potential loss in mouse B16F10 cells at 15 uM after 48 hrs by JC-1 dye based flow cytometry (Rvb = 1.79%)2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1204818Toxicity against mouse xenografted with mouse B16 cells assessed as body weight at 30 mg/kg, ip administered after 7 days of tumor transplantation (Rvb = 18.2 to 18.3 gms)2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID306344Antitumor activity in B16 cells xenografted ICR mouse assessed as tumor weight at 20 mg/kg, ip after 11 days2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1422948Induction of mitochondrial membrane potential loss in mouse B16F10 cells at 7.5 uM after 48 hrs by JC-1 dye based flow cytometry (Rvb = 1.79%)2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1565778Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents.
AID1204817Toxicity against mouse xenografted with human H22 cells assessed as body weight at 30 mg/kg, ip administered after 7 days of tumor transplantation (Rvb = 18.1 to 18.6 gms)2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1862742Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID1862745Selectivity index, ratio of IC50 for cytotoxicity against human HFL1 cells to IC50 for antiproliferative activity against human HT-29 cells overexpressing NQO12022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID600930Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
AID1176849Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered 7 days post inoculation measured at day 25 of tumor transplantation2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
AID306335Cytotoxicity against human SF763 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1422941Antiproliferative activity against HELF after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1422952Induction of apoptosis in mouse B16F10 cells assessed as increase in Bax protein expression at 7.5 to 30 uM after 48 hrs by Western blot analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1889898Inhibition of human CD73 assessed as reduction in inorganic phosphate release upon substrate hydrolysis using AMP/ATP as substrate incubated for 1 hr followed by substrate addition and measured after 2 hrs by malachite green reagent based colorimetric ass2022Bioorganic & medicinal chemistry, 04-01, Volume: 59Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
AID1422956Induction of apoptosis in mouse B16F10 cells assessed as decrease in Bcl2 protein expression at 7.5 to 30 uM after 48 hrs by Western blot analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID306333Cytotoxicity against human A549 cells by MTT assay2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1422954Induction of apoptosis in mouse B16F10 cells assessed as increase in caspase-3 protein expression at 7.5 to 30 uM after 48 hrs by Western blot analysis2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies.
AID1862744Cytotoxicity against human HFL1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID1862780Antitumor activity against human HT-29 cells overexpressing NQO-1 xenografted in ICR mouse assessed as reduction in tumor weight at 30 mg/kg, ip administered every day for 21 days and measured every 2 days relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID306340Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor weight at 20 mg/kg, ip after 4 days2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives.
AID1204815In vivo antitumor activity against human H22 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1165762Antiproliferative activity against human SF763 cells after 72 hrs MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID771495Antibacterial activity against Pseudomonas aeruginosa by dilution technique2013European journal of medicinal chemistry, Oct, Volume: 68Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.
AID1165764Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1165774Toxicity in mouse B6 cells transplanted ICR mouse assessed as mouse survival at 30 mg/kg, ip administered 7 days post tumor transplantation2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
AID1862743Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, Oct-05, Volume: 240Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
AID1204781Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay2015European journal of medicinal chemistry, Jun-05, Volume: 97Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
AID1798302Enzyme Inhibition Assay from Article 10.1021/jm8000949: \\Naturally Occurring Pentacyclic Triterpenes as Inhibitors of Glycogen Phosphorylase: Synthesis, Structure-Activity Relationships, and X-ray Crystallographic Studies.\\2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (23.68)29.6817
2010's23 (60.53)24.3611
2020's6 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.13 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		2.0610benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		7.1110pyrazole
caffeine
[no description available]		2.4520purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.4820aromatic ether;
nitrile;
polyether;
tertiary amino compound
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		3.6180nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.0810C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.0810kanamycinsbacterial metabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.1110diazine;
pyrazines		Daphnia magna metabolite
glycyrrhetinic acid
[no description available]		2.0410cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
oleanolic acid
[no description available]		3.1850hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
paeonol
paeonol: structure		2.0610methoxybenzenes;
phenols		metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		2.0410enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.0710delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.4820taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.4110organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		2.0710carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
ursolic acid
[no description available]		2.7830hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
betulinic acid
[no description available]		4.5470hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		4.2650diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
hederagenin
[no description available]		2.0610dihydroxy monocarboxylic acid;
pentacyclic triterpenoid;
sapogenin		plant metabolite
madecassic acid
[no description available]		2.0410monocarboxylic acid;
pentacyclic triterpenoid;
tetrol		antioxidant;
plant metabolite
arjunolic acid
arjunolic acid: oleanane type; isol from Cochlospermum tinctorium (Bixaceae); structure given in first source; RN given refers to (2alpha,3beta,4alpha)-isomer; RN for cpd without isomeric designation not avail 12/89. arjunolic acid : A pentacyclic triterpenoid that is olean-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). Isolated from Symplocos lancifolia and Juglans sinensis, it exhibits antioxidant and antimicrobial activities.		2.0610hydroxy monocarboxylic acid;
pentacyclic triterpenoid		antibacterial agent;
antifungal agent;
antioxidant;
metabolite
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.4620dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
adriamycinol
doxorubicinol : A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.		2.1110aminoglycoside;
anthracycline antibiotic;
aromatic ether;
deoxy hexoside;
p-quinones;
phenols;
polyol;
tetracenequinones		cardiotoxic agent;
drug metabolite
adenosine 5'-methylenediphosphate
[no description available]		2.4110nucleoside diphosphate analogue
Lup-20(29)-en-28-al, 3beta-hydroxy-
[no description available]		2.4110triterpenoid
asiatic acid
[no description available]		2.4620monocarboxylic acid;
pentacyclic triterpenoid;
triol		angiogenesis modulating agent;
metabolite
betulonic acid
betulonic acid: isolated from Rush javanica; strucure in first source		2.4110triterpenoidanticoronaviral agent
oleuropeic acid
oleuropeic acid: structure in first source		2.2510
lupeol
[no description available]		2.4820pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
rhodamine 123
Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.		2.0810organic cation;
xanthene dye		fluorochrome
3 beta-o-acetylursolic acid
[no description available]		2.0610triterpenoid
beta-escin
[no description available]		2.5420
corosolic acid
[no description available]		2.4620triterpenoidmetabolite
oleanane
oleanane: from the aerial roots of Ficus microcarpa; structure in first source		2.1110terpenoid fundamental parent;
triterpene
palbinone
palbinone: terpenoid isolated from the roots of Paeonia albiflora; structure given in first source; showed strong inhibitory activity against 3-alpha-hydroxysteroid dehydrogenase		2.061016-oxo steroidmetabolite
3-oxo-12-ursen-28-oic acid
3-oxo-12-ursen-28-oic acid: from Potentilla chinensis		2.4620triterpenoid
protopanaxadiol, (3beta,12beta)-isomer
(20S)-protopanaxadiol : A diastereomer of protopanaxadiol in which the 20-hydroxy substituent has been introduced at the pro-S position.		2.0810protopanaxadiol
anemoside a3
anemoside A3: induces relaxation in rat renal arteries; from the root of Pulsatilla chinensis; structure in first source		7.1710
3-epioleanolic acid
[no description available]		2.4620triterpenoidmetabolite
11-deoxy glycyrrhetinic acid
[no description available]		2.4620triterpenoid
oleanonic acid
oleanonic acid: structure in first source		2.4620
augustic acid
[no description available]		2.4620
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		7.4110organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
epi-maslinic acid
epi-maslinic acid : A pentacyclic triterpenoid that is 3alpha-hydroxy epimer of maslinic acid. Isolated from Prunella vulgaris and Isodon japonicus, it exhibits anti-inflammatory activity.		2.4620dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
metabolite
piperidines
Piperidines: A family of hexahydropyridines.		340
benzoylpaeoniflorin
benzoylpaeoniflorin: from Paeonia lactiflora		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Neoplasms
[description not available]		02.0310
Hepatocellular Carcinoma
[description not available]		08.2250
Cancer of Liver
[description not available]		03.5170
B16 Melanoma
[description not available]		02.9940
Benign Neoplasms
[description not available]		02.8430
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		03.2250
Liver Neoplasms
Tumors or cancer of the LIVER.		03.5170
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.8430
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5920
Cancer of Ovary
[description not available]		02.4110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.4110
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.4110
Cancer of Lung
[description not available]		02.7220
Lung Neoplasms
Tumors or cancer of the LUNG.		02.7220
Carcinoma, Non-Small Cell Lung
[description not available]		02.2510
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.2510
Granulocytic Leukemia, Chronic
[description not available]		02.1110
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		02.1110
Cardiac Toxicity
[description not available]		02.1110
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		07.1110
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.9710
Breast Cancer
[description not available]		02.0710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0710
Angiogenesis, Pathologic
[description not available]		02.0310
Adenocarcinoma, Basal Cell
[description not available]		02.0310
Cancer of Colon
[description not available]		02.0310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		07.0310
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310